ERBB2 and breast cancer: Of the 82 participants, two-thirds (n=55, 67%) supported using adjuvant trastuzumab for 6 instead of 12 months in selected patients with HER2-positive breast cancer, such as low-risk patients, older patients, or patients with logistic barriers to receiving the medication during the COVID-19 pandemic.